vTv Therapeutics Inc.
VTVTHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, vTv Therapeutics Inc. (VTVT) is listed under Biotechnology. The company carries a $131.9M market cap, placing it firmly in the micro-cap category. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Market Cap
$131.9M
Beta
0.28
P/E (TTM)
—
P/E (Fwd)
-7.77
EPS (TTM)
$-0.75
EPS (Fwd)
$-4.29
ROE
-15.8%
ROA
-10.1%
Cash
$86.6M
Total Debt
$0
Free CF
$674,375
52W Change
77.7%
Annual Financials
Cash vs Debt
Where VTVT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, VTVT finished 3.22% below its 150-day moving average ($34.51) and 2.77% below its 200-day moving average ($34.35). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VTVT overbought or oversold?
At the September 3, 2026 close, VTVT's RSI(14) was 66.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
vTv Therapeutics Inc. reports $86.6M in cash and $0 in total debt. The company generates $674K in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -15.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $4.0M (2021) to $0 (2025), a 100% decline worth watching.
The relatively low beta of 0.28 suggests VTVT is a less volatile holding compared to the broader index. No single metric tells the full story. Reviewing VTVT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.